Journal
ONCOGENE
Volume 28, Issue 20, Pages 2112-2118Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2009.71
Keywords
CBP; IHD; Mdm4; fluorescence anisotropy; phospho-peptides; transactivation
Funding
- Medical Research Council [MC_U105474168] Funding Source: researchfish
- MRC [MC_U105474168] Funding Source: UKRI
- Medical Research Council [MC_U105474168, U.1054.00.012(74168)] Funding Source: Medline
Ask authors/readers for more resources
The transcriptional activity of the tumour suppressor, p53, requires direct binding between its transactivation domain (TAD, 1-57) and the transcriptional coactivator, p300. We systematically assessed the role of TAD phosphorylation on binding of the p300 domains CH3, Taz1, Kix and IBiD. Thr18 phosphorylation increased the affinity up to sevenfold for CH3 and Taz1, with smaller increases from phosphorylation of Ser20, Ser15, Ser37, Ser33, Ser46 and Thr55. Binding of Kix and IBiD was less sensitive to phosphorylation. Strikingly, hepta-phosphorylation of all Ser and Thr residues increased binding 40- and 80-fold with CH3 and Taz1, respectively, but not with Kix or IBiD. Substitution of all phospho-sites with aspartates partially mimicked the effects of hepta-phosphorylation. Mdm2, the main negative regulator of p53, competes with p300 for binding to TAD. Binding of Mdm2 to TAD was reduced significantly only on phosphorylation of Thr18 (sevenfold) or by hepta-phosphorylation (24-fold). The relative affinities of Mdm2 and p300 for p53 TAD can thus be changed by up to three orders of magnitude by phosphorylation. Accordingly, phosphorylation of Thr18 and hepta-phosphorylation dramatically shifts the balance towards favouring the binding of p300 with p53, and is thus likely to be an important factor in its regulation. Oncogene (2009) 28, 2112-2118; doi:10.1038/onc.2009.71; published online 13 April 2009
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available